Healthcare Equipment and Supplies
Company Overview of nContact, Inc.
nContact, Inc. is an ablation company that engages in the development of arrhythmia and cardiovascular disease management programs for cardiac arrhythmias. The company offers ablation system devices to ensure consistent and predictable contact with cardiac tissue during the creation of linear lesions. Its solutions include EPi-Sense devices with embedded electrodes that allow for sensing and navigation of the epicardium; EPi-Sense Guided Coagulation Device with VisiTrax that integrates suction, perfusion, and RF energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart; The Cannula that allows surgeons direct visualization while ablating on t...
1001 Aviation Parkway
Morrisville, NC 27560
Founded in 2004
Key Executives for nContact, Inc.
Co-Founder and Vice President of Research & Clinicals
Co-Founder and Vice President of Development & Operations
Vice President of Finance
Compensation as of Fiscal Year 2015.
nContact, Inc. Key Developments
AtriCure, Inc., nContact, Inc. - M&A Call
Oct 5 15
To discuss AtriCure definitive agreement to acquire nContact
nContact Appoints William Hawkins as Chairman of its Board of Directors
Jul 21 15
nContact announced that William (Bill) Hawkins has been appointed as Chairman of its Board of Directors. Bill Hawkins has served as a special advisor to the nContact Board since 2013 and is a veteran entrepreneur and executive in the medical device arena, with more than 20 years of C-Suite experience in cardiology, surgery, and vascular therapies. Most recently, Bill was President and CEO of Immucor.
nContact Secures $20 Million in Growth Capital Financing
Nov 12 14
nContact announced that it has entered into a $20 million growth capital financing agreement with Hercules Technology Growth Capital, Inc. The company plans to use this financing to support its ongoing CONVERGE IDE Clinical Trial, expand its field support teams, and further next-generation product development. The randomized CONVERGE IDE clinical trial is the first head-to-head study comparing the multidisciplinary Convergent Procedure to traditional catheter ablation in the treatment of persistent AF. AF is the most common arrhythmia, affecting 15 million people in the western world, with an estimated 88% falling into the difficult-to-treat persistent AF population. The CONVERGE clinical trial randomizes patients 2:1 between the epicardial-endocardial Convergent Procedure and endocardial-only ablation with fluid-irrigated catheters.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 4, 2015
Most Searched Private Companies
Sponsored Financial Commentaries